Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany

Abstract

Background Steady evolution of therapies has improved prognosis of patients with multiple myeloma (MM) over the past two decades. Yet, knowledge about survival trends and causes of death in MM might play a crucial role in long-term management of this patient collective. Here, we investigate time trends in myeloma-specific survival at the population level over two decades and analyse causes of death in times of prolonged survival. Methods Age-standardised and age group-specific relative survival (RS) of MM patients aged < 80 years at diagnosis was estimated for consecutive time periods from 2000–2019 using data from the Cancer Registry of North Rhine-Westphalia in Germany. Conditional RS was estimated for patients who already survived one to five years post diagnosis. Causes of death in MM patients were analysed and compared to the general population using standardised mortality ratios (SMR). Results Three thousand three hundred thirty-six MM cases were included in the time trend analysis. Over two decades, age-standardised 5-year RS increased from 37 to 62%. Age-specific survival improved from 41% in period 2000–2004 to 69% in period 2015–2019 in the age group 15–69 years, and from 23 to 47% in the age group 70–79 years. Conditional 5-year RS of patients who survived five years after diagnosis slightly improved as compared to unconditional 5-year RS at diagnosis. MM patients are two times more likely to die from non-myeloma malignancies (SMR = 1.97, 95% CI 1.81–2.15) and from cardiovascular diseases (SMR = 2.01, 95% CI 1.86–2.18) than the general population. Conclusions Prognosis of patients with MM has markedly improved since the year 2000 due to therapeutic advances. Nevertheless, late mortality remains a major concern. As survival improves, second primary malignancies and cardiovascular events deserve increased attention.

Multiple Myeloma Presenting With Bronchopneumonia: A Case Report

“…The five-year survival rate of multiple myeloma is around 57%, and the prognosis has increased due to therapeutic advances [ 6 ]. Multiple myeloma should be classified into high- or standard-risk groups, and proper treatment regimens should be initiated in such a way that future treatment is unaffected.…”

A comparative analysis of transcriptomics of newly diagnosed multiple myeloma: exploring drug repurposing

“…The treatment decision is currently based on age, performance status and risk stratification ( 7 ). Age-standardized five-year survival has increased from 41% to 69% for patients under 69 years old and from 23% to 47% for patients between 70 and 79 years old ( 8 ). Despite significant progress, MM remains incurable and inevitably all patients will experience relapses and eventually develop refractory disease.…”

Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma

“…Much progress has been made in the past 20 years. Real-world studies showed that the 5-year survival rate increased from 37 to 62% (years 2000–2019) in a German population [ 2 ] and increased from 27 to 47% (years 1994–2016) in a Spanish population [ 3 ]. These successes can be attributed to the development of more effective therapies; however, patients will eventually develop relapsed and/or refractory MM (RRMM) and require further therapy [ 4 , 5 ].…”